Genesis Biopharma appoints new ceo and cfo
Anthony Cataldo and Michael Handelman also join board of directors
In addition Genesis Biopharma has appointed Michael Handelman as chief financial officer, treasurer and secretary, succeeding Richard McKilligan.
Cataldo and Handelman have joined the company's Board, while Brooke, McKilligan and Mark Ahn have resigned as members.
‘I'm looking forward to working with the Genesis Biopharma board to further the progress of our important cancer technology, and to develop new strategic opportunities to build shareholder value,’ said Cataldo.
‘Genesis Biopharma's targeted anti-CD55 monoclonal antibody technology has widespread clinical utility, as it neutralises a key cancer defence mechanism that is over-expressed in more than 80% of tumours. It could provide a safe alternative to toxic chemotherapy regimens, and has the potential to expand and improve the clinical utility of already approved antibody therapies as well as some novel agents in development.’
Cataldo was formerly chairman, chief executive and a director of Oxis International. Prior to this he was non-executive co-chairman of the Board of MultiCell Technologies.
Handelman was chief financial officer of Oxis International. Prior to this he was cfo and coo of TechnoConcepts.
You may also like
Research & Development
Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases
The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases